-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Natural killer cells (NK) are important immune cells in the body, not only related to anti-tumor, antiviral infection and immunomodulation, but also in some cases involved in hypersensitivity and the occurrence of autoimmune diseases, can identify target cells.
immuno-oncology company GT Biopharma announced today that it has filed a U.S. and international patent application and has initiated clinical development of NK Cell Joint (TriKE™) to treat HER2 plus, HER3 plus and HER2 plus / HER3 plus breast and gastrointestinal cancer.
NK Cell Joint (TriKE™) consists of a single-chain trisexual scFv recombinant fusion protein affix, which consists of heavy chain and light chain variable zones resistant to CD16 and HER2 antibodies, as well as an improved form of IL-15.
part of human IL-15 provides a self-sustaining signal of natural killer (NK) cells that activates NK cells and enhances their ability to kill cancer cells.
The TriKE™ has shown good results in animal models, enabling us to start clinical trials and start GMP production," commented Anthony Cataldo, Chairman and CEO of GT Biopharma.
。